Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.

What was studied

This was a review of drugs for Sjögren's disease. It is an autoimmune disorder. It mainly harms glands that make fluids. It also hits other organs in mixed ways. Care once focused on easing symptoms. The team searched PubMed, Web of Science, Embase and the Cochrane Library.

What they found

New immune science has deepened how the disease is seen. Care is moving from symptom relief to targeted drugs. Drugs under study deplete B-cells or block BAFF/APRIL. Others block interferon or JAK-STAT. Some change how T-cells and B-cells meet. The pipeline is growing fast.

What it means for patients

The authors said the most effective drugs will likely need biomarkers. These should fit specific biological endotypes. CAR-T therapy in refractory disease is an emerging, experimental approach. They said it needs rigorous review of safety and long-term feasibility.

Why it is not certain yet

CAR-T therapy is strictly experimental. Its safety and long-term feasibility need rigorous review. This is an expert opinion, not a pooled analysis. The abstract gives no patient numbers or outcomes.

Source

Immunosuppressive and immunomodulatory therapies in Sjögren's disease: current landscape and future perspectives.

We restate facts from the source record in our own words. The original wording belongs to its publisher.